Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Hydrocortisone acetate. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hydrocortisone acetate. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Hydrocortisone acetate. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Hydrocortisone acetate. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hydrocortisone acetate. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Hydrocortisone acetate. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Hydrocortisone acetate. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrocortisone acetate. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone acetate. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone acetate. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydrocortisone acetate. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydrocortisone acetate. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone acetate. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone acetate. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone acetate. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone acetate. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone acetate. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone acetate. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Hydrocortisone acetate. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydrocortisone acetate. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone acetate. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydrocortisone acetate. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone acetate. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Hydrocortisone acetate. |
| Cladribine | Hydrocortisone acetate may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Hydrocortisone acetate. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Hydrocortisone acetate. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Hydrocortisone acetate. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Hydrocortisone acetate. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Hydrocortisone acetate. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Hydrocortisone acetate. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Hydrocortisone acetate. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Hydrocortisone acetate. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Hydrocortisone acetate. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hydrocortisone acetate. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Hydrocortisone acetate. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Hydrocortisone acetate. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Hydrocortisone acetate. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Hydrocortisone acetate. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Hydrocortisone acetate. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Hydrocortisone acetate. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Hydrocortisone acetate. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Hydrocortisone acetate. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydrocortisone acetate. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hydrocortisone acetate. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Hydrocortisone acetate. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Hydrocortisone acetate. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydrocortisone acetate. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Hydrocortisone acetate. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Hydrocortisone acetate. |
| Tretinoin | The metabolism of Hydrocortisone acetate can be decreased when combined with Tretinoin. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Hydrocortisone acetate. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Hydrocortisone acetate. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Hydrocortisone acetate. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Hydrocortisone acetate. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Hydrocortisone acetate. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Hydrocortisone acetate. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Hydrocortisone acetate. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Hydrocortisone acetate. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone acetate. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Hydrocortisone acetate. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Hydrocortisone acetate. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Hydrocortisone acetate. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Hydrocortisone acetate. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Hydrocortisone acetate. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Hydrocortisone acetate. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Hydrocortisone acetate. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Hydrocortisone acetate. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydrocortisone acetate. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Hydrocortisone acetate. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Hydrocortisone acetate. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Hydrocortisone acetate. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Hydrocortisone acetate. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Hydrocortisone acetate. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Hydrocortisone acetate. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Hydrocortisone acetate. |
| Stepronin | The risk or severity of adverse effects can be increased when Stepronin is combined with Hydrocortisone acetate. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Hydrocortisone acetate. |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Hydrocortisone acetate. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Hydrocortisone acetate. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Hydrocortisone acetate. |
| Brequinar | The risk or severity of adverse effects can be increased when Brequinar is combined with Hydrocortisone acetate. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Hydrocortisone acetate. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Interferon alfa is combined with Hydrocortisone acetate. |
| Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Hydrocortisone acetate. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Hydrocortisone acetate. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Hydrocortisone acetate. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Hydrocortisone acetate. |
| Abetimus | The risk or severity of adverse effects can be increased when Abetimus is combined with Hydrocortisone acetate. |
| Belatacept | The risk or severity of adverse effects can be increased when Belatacept is combined with Hydrocortisone acetate. |
| Bendamustine | The risk or severity of adverse effects can be increased when Bendamustine is combined with Hydrocortisone acetate. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Pralatrexate is combined with Hydrocortisone acetate. |
| Wortmannin | The risk or severity of adverse effects can be increased when Wortmannin is combined with Hydrocortisone acetate. |
| Eribulin | The risk or severity of adverse effects can be increased when Eribulin is combined with Hydrocortisone acetate. |
| Belimumab | The risk or severity of adverse effects can be increased when Belimumab is combined with Hydrocortisone acetate. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Teriflunomide is combined with Hydrocortisone acetate. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Carfilzomib is combined with Hydrocortisone acetate. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Hydrocortisone acetate. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Hydrocortisone acetate. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Vedolizumab is combined with Hydrocortisone acetate. |